Lee Jae-Sug, Choi Hwa-Jung, Song Jae-Hyoung, Ko Hyun-Jeong, Yoon Kyungah, Seong Jeong-Min
Department of Beauty Science, Kwangju Women's University, Gwangju, Korea.
Laboratory of Microbiology and Immunology, College of Pharmacy, Kangwon National University, Chuncheon, Korea.
Osong Public Health Res Perspect. 2017 Oct;8(5):318-324. doi: 10.24171/j.phrp.2017.8.5.05. Epub 2017 Oct 31.
Echovirus 30 is a major cause of meningitis in children and adults. The aim of this study was to investigate whether the antifungal drug itraconazole could exhibit antiviral activity against echovirus 30.
The cytopathic effect and viral RNA levels were assessed in RD cells as indicators of viral replication. The effects of itraconazole were compared to those of two known antiviral drugs, rupintrivir and pleconaril. The time course and time-of-addition assays were used to approximate the time at which itraconazole exerts its activity in the viral cycle.
Itraconazole and rupintrivir demonstrated the greatest potency against echovirus 30, demonstrating concentration-dependent activity, whereas pleconaril showed no antiviral activity. Itraconazole did not directly inactivate echovirus 30 particles or impede viral uptake into RD cells, but did affect the initial stages of echovirus 30 infection through interference with viral replication.
Itraconazole can be considered a lead candidate for the development of antiviral drugs against echovirus 30 that may be used during the early stages of echovirus 30 replication.
肠道病毒30型是儿童和成人脑膜炎的主要病因。本研究的目的是调查抗真菌药物伊曲康唑是否对肠道病毒30型具有抗病毒活性。
在RD细胞中评估细胞病变效应和病毒RNA水平，作为病毒复制的指标。将伊曲康唑的效果与两种已知抗病毒药物鲁平替尼和普来可那立的效果进行比较。采用时间进程和添加时间试验来估算伊曲康唑在病毒周期中发挥活性的时间。
伊曲康唑和鲁平替尼对肠道病毒30型显示出最大效力，表现出浓度依赖性活性，而普来可那立未显示抗病毒活性。伊曲康唑不会直接使肠道病毒30型颗粒失活或阻碍病毒进入RD细胞，但确实通过干扰病毒复制影响肠道病毒30型感染的初始阶段。
伊曲康唑可被视为开发针对肠道病毒30型的抗病毒药物的主要候选药物，这些药物可在肠道病毒30型复制的早期阶段使用。
Zotero 插件
